HK1142128A1 - Methods of prognosis - Google Patents

Methods of prognosis

Info

Publication number
HK1142128A1
HK1142128A1 HK10108448.9A HK10108448A HK1142128A1 HK 1142128 A1 HK1142128 A1 HK 1142128A1 HK 10108448 A HK10108448 A HK 10108448A HK 1142128 A1 HK1142128 A1 HK 1142128A1
Authority
HK
Hong Kong
Prior art keywords
prognosis
methods
Prior art date
Application number
HK10108448.9A
Other languages
English (en)
Chinese (zh)
Inventor
Samuel Norbert Breit
David Alexander Brown
Henrik Grnberg
Original Assignee
St Vincents Hospital Sydney Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2007905761A external-priority patent/AU2007905761A0/en
Application filed by St Vincents Hospital Sydney Ltd filed Critical St Vincents Hospital Sydney Ltd
Publication of HK1142128A1 publication Critical patent/HK1142128A1/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK10108448.9A 2007-10-22 2010-09-06 Methods of prognosis HK1142128A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2007905761A AU2007905761A0 (en) 2007-10-22 Methods of prognosis
PCT/AU2008/001554 WO2009052557A1 (en) 2007-10-22 2008-10-22 Methods of prognosis

Publications (1)

Publication Number Publication Date
HK1142128A1 true HK1142128A1 (en) 2010-11-26

Family

ID=40578957

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10108448.9A HK1142128A1 (en) 2007-10-22 2010-09-06 Methods of prognosis

Country Status (8)

Country Link
US (4) US20110039284A1 (xx)
EP (1) EP2208072B1 (xx)
JP (2) JP5272011B2 (xx)
CN (1) CN101861522B (xx)
CA (1) CA2701945A1 (xx)
ES (1) ES2543985T3 (xx)
HK (1) HK1142128A1 (xx)
WO (1) WO2009052557A1 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017671A1 (en) 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
ES2434996T3 (es) 2008-10-31 2013-12-18 St Vincent's Hospital Sydney Limited Métodos de pronóstico en enfermedad renal crónica
WO2011050407A1 (en) * 2009-10-28 2011-05-05 St Vincent's Hospital Sydney Limited Methods of diagnosing and prognosing colonic polyps
EP2573566A1 (en) * 2011-09-20 2013-03-27 Atlas Antibodies AB RBM3 in prostate cancer prognostics
US9550819B2 (en) 2012-03-27 2017-01-24 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
CA2899170C (en) 2013-01-30 2022-08-02 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
MX2016012667A (es) 2014-03-28 2017-01-09 Opko Diagnostics Llc Composiciones y metodos relacionados con el diagnostico de cancer de prostata.
WO2016018931A1 (en) 2014-07-30 2016-02-04 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
AU2015339130C1 (en) 2014-10-31 2021-03-18 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
WO2016110782A1 (en) * 2015-01-05 2016-07-14 University Of Oslo Prostate cancer markers and uses thereof
CN107406510B (zh) 2015-03-27 2022-02-18 欧普科诊断有限责任公司 前列腺抗原标准品及其用途
CN108700573B (zh) * 2016-02-29 2021-06-11 公立大学法人横滨市立大学 检测去势抵抗性前列腺癌的方法和检测试剂
PE20190126A1 (es) 2016-03-31 2019-01-17 Ngm Biopharmaceuticals Inc Proteinas de union y metodos de uso de las mismas
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003599A1 (en) * 1992-08-04 1994-02-17 Sagami Chemical Research Center HUMAN cDNA AND PROTEIN WHICH SAID cDNA CODES FOR
US6180602B1 (en) * 1992-08-04 2001-01-30 Sagami Chemical Research Center Human novel cDNA, TGF-beta superfamily protein encoded thereby and the use of immunosuppressive agent
US5994102A (en) * 1994-12-15 1999-11-30 Human Genome Sciences, Inc. Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
US6521227B1 (en) * 1999-11-18 2003-02-18 Peter L. Hudson Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
KR20030097607A (ko) * 1996-09-30 2003-12-31 휴먼 게놈 사이언시즈, 인코포레이티드 골수양 선조 세포 억제 인자-1(ｍｐｉｆ-1)를 이용하여질병 상태를 치료하기 위한 치료 조성물 및 치료 방법
WO1999006445A1 (en) * 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
US6465181B2 (en) * 1999-03-25 2002-10-15 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
DE60142372D1 (de) * 2000-04-20 2010-07-22 St Vincents Hosp Sydney Diagnostischer Assay mit makrophagenhemmendem Zytokin-1 (MIC-1)
WO2002059373A2 (en) * 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
WO2002092124A1 (en) * 2001-05-11 2002-11-21 Wyeth Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof
AU2002335640A1 (en) * 2001-08-17 2003-03-03 Affymetrix, Inc. Gleason grade 4/5 prostate cancer genes
US20030211531A1 (en) * 2002-05-01 2003-11-13 Irm Llc Methods for discovering tumor biomarkers and diagnosing tumors
US7157235B2 (en) * 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US7919084B2 (en) * 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer

Also Published As

Publication number Publication date
JP5272011B2 (ja) 2013-08-28
JP2013174614A (ja) 2013-09-05
US20110039284A1 (en) 2011-02-17
ES2543985T3 (es) 2015-08-26
CN101861522B (zh) 2014-05-14
EP2208072B1 (en) 2015-07-01
EP2208072A4 (en) 2011-01-26
WO2009052557A1 (en) 2009-04-30
CN101861522A (zh) 2010-10-13
US20230059466A1 (en) 2023-02-23
US20160018401A1 (en) 2016-01-21
EP2208072A1 (en) 2010-07-21
US20200003780A1 (en) 2020-01-02
JP5734342B2 (ja) 2015-06-17
JP2011501136A (ja) 2011-01-06
CA2701945A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
HK1142128A1 (en) Methods of prognosis
GB0706709D0 (en) Methods
GB0711697D0 (en) Method of manufacture
ZA201001878B (en) Improved detection of mage-a-expression
HK1132673A1 (en) Novel methods
AP2008004406A0 (en) Methods of managing timberland
EP2234642A4 (en) METHOD FOR INCREASING AN IMMUNOLOGICAL EFFECT
IL201054A0 (en) New methods
GB0705854D0 (en) Methods of construction
GB0718160D0 (en) Methods
AP2784A (en) Methods of managing timberland
EP2342355A4 (en) METHODS OF USING BIOMARKERS
GB0701599D0 (en) Method of detection
ZA200900636B (en) Method of prognosis
EP2161998A4 (en) NOVEL PROCEDURE
EP2205524A4 (en) METHODS OF MANUFACTURING CLUSTER BORON
GB0715502D0 (en) Methods
GB0714842D0 (en) Methods
GB0707735D0 (en) Methods
TWI348657B (en) Determination method of edge direction
GB0711140D0 (en) New methods
GB201114396D0 (en) Location of basesation
GB0719252D0 (en) Methods
GB0713673D0 (en) Methods
AU2007905761A0 (en) Methods of prognosis

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: GR